Abstract: A highly specific surface for biological reactions, which includes a support with at least one essentially compact layer of an organic compound. On the outside of the organic compound layer is an exposed group containing an ethylenic double bond, which has affinity for a molecule with biological activity under certain reaction conditions. The other elements of the organic compound layer are essentially inaccessible to the molecule with biological activity under the reaction conditions.

Abstract: A nucleotide sequence encoding a katG/lacZ fusion protein is useful for assaying the enzymatic activity of the katG gene product. A process of selecting a compound that is toxic against an isoniazid-resistant mycobaterial strain comprises incubating a catalase peroxidase enzyme with an isoniazid to produce a compound that restores isoniazid susceptability to the isoniazid-resistant mycobaterial strain.

Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

Abstract: A nucleotide sequence coding for at least one part of the terminal N region of a polypeptide which exercises a specific toxic effect on Lepidoptera of the Noctuidae family, preferably on S.littoralis, is characterized by its capacity for hybridization with a gene capable of expressing a polypeptide exercising a toxic effect on S.littoralis larvae.

Abstract: The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS. 1a and 1b respectively:76-556543-864867-28112728-38083326-35753842-40794198-56115516-8091.The invention also relates to the use of these fragments as probes for the detection of HPV in tissue cultures.

Abstract: An in vitro, single cycle, recombinant virus assay (RVA) for determining inhibition of HIV replication by a protease inhibitor comprises transfecting a human epithelial cell line with amplified HIV protease sequences of an HIV virus; an HIV, envelope defective, molecular clone having a complete deletion of its protease coding sequence; and a plasmid containing HIV envelope coding sequence under the control of a promoter for phenotypic complementation of the envelope defective molecular clone. The transfected cells are cultured in the presence of a protease inhibitor to produce a testable stock of infectious particles that can be used to infect indicator cells containing an indicator gene without amplification of the infectious particles prior to infecting the indicator cells. Accumulation of indicator gene product is a measure of inhibition of HIV replication by the protease inhibitor.

Abstract: The invention relates to a polypeptide characterized in that it contains at least one peptide sequence carrying one or several epitopes characteristic of a protein produced at the sporozoite stage and in the hepatocytes infected by P. falciparum, this sequence comprising a sequence of from 10 amino acids to the maximal number of amino acids of the following peptide chain sequence:Glu-Phe-Arg-Val-Ser-Thr-Ser-Asp-Thr-Pro-Gly-Gly-Asn-Glu-Ser-Ser-Ser-Ala-Phe -Pro-Gln-Phe-Ile-Trp-Ser-Ala-Glu-Lys-Lys-Asp-Glu-Lys-Glu-Ala-Ser-Glu-Gln-Gl y-Glu-Glu-Ser-His-Lys-Lys-Glu-Asn-Ser-Gln-Glu-Ser-Ala-Asn-Gly-Lys-Asp-Asp-V al-Lys-Glu-Glu-Lys-Lys-Thr-Asn-Glu-Lys-Lys-Asp-Asp-Gly-Lys-Thr-Asp-Lys-Val- Gln-Glu-Lys-Val-Leu-Glu-Lys-Ser-Pro-Lys-Glu-Phe.It also relates to the use of these polypeptides, as well as the nucleotide sequences coding for these polypeptides, in methods of in vitro diagnosis of malaria on a biological sample derived from the individual in whom the disease is to be detected.

Abstract: A process produces DNA corresponding to that of the DNA of the virus of B hepatitis. It comprises cloning in bacteria the latter DNA, previously repaired by means of the corresponding precursor nucleotides in the presence of a polymerase. Vectors contain the cloned DNA in their genomes. The cloned DNA is useful as a probe for detecting the presence of the virus of B hepatitis in biological samples, particularly blood or plasma. Its expression in bacteria provides a hybrid protein containing a protein fragment having vaccinating properties against hepatitis B. Nucleic acid of reduced size and a vector containing the nucleotide sequence of which DNA codes an immunogenic peptide sequence capable of inducing the generation of antibodies to the virus of viral hepatitis B. It comprises totally or partly the sequence of nucleotides represented in FIG. 9A.

Abstract: A process for replacing a nucleotide sequence in the genome of a mycobacterium strain comprises the steps of:a) providing a vector containing SacB gene coding for levane saccharase enzyme and a nucleotide sequence of interest;b) transfecting the mycobacterium strain with the vector;c) selecting clones of the resulting transfected mycobacteria for replacement of the nucleotide sequence of interest by propagating the transfected clones in a culture medium supplemented with sucrose; andd) isolating the recombinant strain.The process is useful for positive selection of allelic exchange mutants, such as in Mycobacterium tuberculosis complex.

Abstract: The present invention relates particularly to a strain of Bacillus thuringiensis characterized in that it expresses the gene sigma E (.sigma.E) and does not sporulate at all or little sporulates or does not produce any viable spores. The invention also relates to a pesticide composition containing said strain of Bacillus thuringiensis.

Abstract: Composition for use in the treatment of tumors and the immunization of humans or animals comprising a synergistic association of cells, viruses, or bacteria expressing, transitorily, in organisms at least one gene for producing in vivo one or more immunomodulators, and viruses, or cells producing viruses, said viruses preferably infecting dividing cells of the treated organisms and carrying within their genome at least one gene whose expression in the dividing cells will cause their destruction.

Abstract: The invention relates to a protein VanB involved, in Gram-positive bacteria, in resistance to glycopeptides, particularly to vancomycine, said resistance being of the type inducible by the vancomycine and non-inducible by teicoplanine. The invention also relates to the utilisation of fragments of nucleotides of the gene van B for the detection of resistances to glycopeptides.

Abstract: The subject of the invention is new means, comprising nucleotide sequences, for the detection, especially after amplification, of the DNA or of the cDNA of S. enterica or S. bongori.The invention relates especially to the oligonucleotides represented in the abstract figure.

Abstract: Compositions which comprise one or more B epitopes of the envelope glycoprotein of a retrovirus and one or more T epitope of the envelope glycoprotein from a distinct retrovirus, or a Tepitope from a different protein of the same retrovirus as the B epitope. In particular, the retrovirus is a human immunodeficiency virus (HIV) or a simian immunodeficiency virus (SIV), human T-cell lymphotropic virus type I (HTLV-I), or a human T-cell lymphotropic virus type II (HTLV-II).

Abstract: Composition designed to treat human or animal organisms comprising cells expressing genes enabling them to secrete in vivo one or more biologically-active substances, said cells exhibiting genetic characteristics preventing them from growing durably in the treated organism, and making them susceptible to elimination artificially or naturally from the organism. These compositions can be used in particular in the treatment of tumors or cancers, in which case the substances used are interleukins. The cells contained in these compositions are at least partially allogenic or xenogenic.

Abstract: Shuttle vectors for inserting DNA in mycobacteria comprising at least one origin of functional replication in said mycobacteria, another origin of functional replication in other bacteria, an enzyme cutting site allowing the insertion of DNA coding for a protein capable of being expressed in the mycobacteria, characterized in that they also carry a gene providing on said mycobacteria resistance to a compound containing a heavy metal.

Abstract: The cytA gene encoding the 28 kDa polypeptide of Bacillus thuringiensis israelensis crystals was disrupted in the 72 MDa resident plasmid by in vivo recombination. The absence of the 28 kDa protein in B. thuringiensis israelensis did not affect the crystallization of the other toxic components of the parasporal body. However, the absence of the 28 kDa protein did abolish the hemolytic activity of B. thuringiensis serovar israelensis crystals. The mosquitocidal activity of the 28 kDa protein-free crystals did not differ significantly from the wild-type crystals.

Abstract: The invention relates to a sequence of nucleotides characterized in that it corresponds to the fragment HindIII of about 4.3 kb which can be obtained from the plasmid pJEG80.1 which has been deposited at the CNCM on Aug. 23, 1994 with the number I-1469 or capable of hybridizing in stringent conditions with said plasmid. It also relates to polypeptides resulting from the expression of said sequence and their utilization in toxic compositions against insects.

Abstract: Mycobacterium proteins, in particular those of M. bovis, having molecular weights between approximately 44.5 and 47.5 kD. These proteins can have molecular weights of approximately 45 kD or 47 kD and isoelectric pH of approximately 3.7 (45 and 47 kD proteins) and 3.9 (47 kD proteins).These proteins or hybrid proteins containing a part of their sequences can be used as vaccines or as drugs, or for the detection and monitoring of tuberculosis in particular in man and in cattle.

Abstract: This invention is directed to a composition comprising one or more human immunodeficiency virus type 2 (HIV-2) envelope proteins and a pharmaceutically acceptable carrier. The proteins of the claimed invention are gp300, p200 and p90/80 of HIV-2. The composition is useful for the diagnostic assay of HIV-2 and as an antigen for the production of antibodies, for example.